AngioSoma’s Corporate Focus
Business Wire: July 14, 2016 – MONTGOMERY, TX, U.S.A. – AngioSoma, Inc. (OTCQB: SOAN), previously known as First Titan Corp. (the “company,” “we,” and “our”), changed our corporate name and focus to that of a clinical-stage biopharmaceutical company, introducing an exciting new treatment for one of the world’s most insidious and pervasive diseases, peripheral artery disease (PAD). The introduction of this new drug, Liprostin™, a liposomal controlled release encapsulation of prostaglandinE1 (PGE1), will greatly improve the effectiveness of the drug and of current standard-of-care treatments, especially when used with endovascular interventions such as transluminal percutaneous angioplasty, stenting, and atherectomy interventions in the treatment of PAD. The company’s strengths include our research team, flagship product Liprostin™, intellectual property pipeline, and legacy oil and gas assets.
Our research team, headed by chairman emeritus Dr. David P. Summers, PhD, is a multi-talented, seasoned collection of applied scientists and medical field specialists assembled to produce product and market results—“this isn’t their first rodeo!” Dr. Summers’s biotechnical experience as both an engineer and biotechnical scientist bringing intellectual property to market is extensive, spanning multiple decades. “Working with Dr. Summers is an absolute pleasure! His long history of leading research teams from product and technology conceptualization, through product development, and then to product sales is amazing,” said Alex Blankenship, AngioSoma, Inc.’s CEO.
Liprostin™, our flagship product, is an FDA-approved product in a new controlled delivery system, a sterically stable liposome that has made our product, the well-known generic prostaglandinE1 (PGE1), a brand new drug with a brand new controlled delivery. The Liprostin™ market is a very large multi-billion-dollar international market. There are many derivative treatments such as diabetes, peripheral neuropathies, and various vascular disorders that may be candidates for treatment once FDA approval is obtained, and information amassed by our research team will provide a continuous stream of intellectual property (IP), yielding future patent protection and future products.
Our intellectual property pipeline is large and has expired or expiring patents providing a basis for new product development, patent applications, and research, continually enlarging the pipeline and future products even further
The company still owns assets in the oil and gas industry that may provide independent shareholder value in the future. We have already begun to explore various strategies to unlock this shareholder value while not detracting from our current focus.
AngioSoma, Inc. (www.angiosoma.com), a Nevada corporation based in Montgomery, Texas, is a clinical-stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD). Our lead pharmaceutical product, Liprostin™, for the treatment of PAD, has successfully completed FDA phase I and three phase II clinical trials, and we are in discussions with several contract research organizations (CROs) for rapid completion of our U.S. Food and Drug Administration (FDA) approved protocol for phase III with submission of our new drug application (NDA) for marketing in the United States and its territories.
